AstraZeneca outlines restructuring as earnings show cost cuts, while Alnylam slides and Regeneron posts record quarter

AstraZeneca said it will redeploy resources through a new restructuring program aimed at cutting costs while staying on track to hit its long‑term revenue goal of $80 billion by 2030. The company highlighted that it has already brought four new medicines to market and reported positive data from 12 late‑stage trials.

In its latest earnings release, the firm reiterated confidence that the restructuring will support its growth plan, noting that up to 20 high‑value trial readouts could generate more than $20 billion in annual revenue if they prove successful.

Alnylam Pharmaceuticals saw its shares fall after investors expressed worries about the outlook for its leading drug candidate, prompting a sell‑off in the stock.

Regeneron, by contrast, posted a record quarterly performance that was well received by the market, with investors rewarding the company for its strong results.